Jacob Fredsted, MSc, serves as Senior Scientist, Drug Substance Development, CMC at Hemab and has 10 years of experience in the biotechnology industry across early- and late-stage process development as well as commercial manufacturing. With experience in monoclonal -and bispecific antibodies, antibody-drug conjugates, and recombinant proteins, he has been involved in Process Characterization, Performance Qualification, submission- and approval by EMA and FDA. Prior to joining Hemab, he worked at Novo Nordisk, AGC Biologics, and most recently as CMC Specialist at Genmab. He earned a Master of Science in Biochemistry from the University of Copenhagen, Denmark.